Switch theme
Sign up to access all valuation multiples
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
1995
40.6K+
LTM Revenue $5.8B
LTM EBITDA $971M
$11.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fosun Pharma has a last 12-month revenue (LTM) of $5.8B and a last 12-month EBITDA of $971M.
In the most recent fiscal year, Fosun Pharma achieved revenue of $5.7B and an EBITDA of $1.2B.
Fosun Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fosun Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.8B | XXX | $5.7B | XXX | XXX | XXX |
| Gross Profit | $2.9B | XXX | $2.7B | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $971M | XXX | $1.2B | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $524M | XXX | $445M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $407M | XXX | $384M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fosun Pharma's stock price is CNY 23 (or $3).
Fosun Pharma has current market cap of CNY 62.1B (or $8.6B), and EV of CNY 82.3B (or $11.4B).
See Fosun Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.4B | $8.6B | XXX | XXX | XXX | XXX | $0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fosun Pharma has market cap of $8.6B and EV of $11.4B.
Fosun Pharma's trades at 2.0x EV/Revenue multiple, and 9.6x EV/EBITDA.
Equity research analysts estimate Fosun Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fosun Pharma has a P/E ratio of 21.2x.
See valuation multiples for Fosun Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.6B | XXX | $8.6B | XXX | XXX | XXX |
| EV (current) | $11.4B | XXX | $11.4B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.8x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 21.8x | XXX | 25.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.2x | XXX | 22.4x | XXX | XXX | XXX |
| EV/FCF | 23.6x | XXX | 1231.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFosun Pharma's last 12 month revenue growth is 6%
Fosun Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Fosun Pharma's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fosun Pharma's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fosun Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fosun Pharma acquired XXX companies to date.
Last acquisition by Fosun Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Fosun Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fosun Pharma founded? | Fosun Pharma was founded in 1995. |
| Where is Fosun Pharma headquartered? | Fosun Pharma is headquartered in China. |
| How many employees does Fosun Pharma have? | As of today, Fosun Pharma has 40.6K+ employees. |
| Who is the CEO of Fosun Pharma? | Fosun Pharma's CEO is Mr. Deyong Wen. |
| Is Fosun Pharma publicy listed? | Yes, Fosun Pharma is a public company listed on SHG. |
| What is the stock symbol of Fosun Pharma? | Fosun Pharma trades under 600196 ticker. |
| When did Fosun Pharma go public? | Fosun Pharma went public in 1998. |
| Who are competitors of Fosun Pharma? | Similar companies to Fosun Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Fosun Pharma? | Fosun Pharma's current market cap is $8.6B |
| What is the current revenue of Fosun Pharma? | Fosun Pharma's last 12 months revenue is $5.8B. |
| What is the current revenue growth of Fosun Pharma? | Fosun Pharma revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Fosun Pharma? | Current revenue multiple of Fosun Pharma is 2.0x. |
| Is Fosun Pharma profitable? | Yes, Fosun Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fosun Pharma? | Fosun Pharma's last 12 months EBITDA is $971M. |
| What is Fosun Pharma's EBITDA margin? | Fosun Pharma's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Fosun Pharma? | Current EBITDA multiple of Fosun Pharma is 11.8x. |
| What is the current FCF of Fosun Pharma? | Fosun Pharma's last 12 months FCF is $485M. |
| What is Fosun Pharma's FCF margin? | Fosun Pharma's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Fosun Pharma? | Current FCF multiple of Fosun Pharma is 23.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
